| Harbour Health Center | |
| 23013 Westchester Blvd, Port Charlotte, Florida 33980 | |
| (941) 625-1220 | |
| Name | Harbour Health Center |
|---|---|
| Location | 23013 Westchester Blvd, Port Charlotte, Florida |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 120 |
| Occupancy Rate | 74.33% |
| Medicare ID (CCN) | 105538 |
| Legal Business Name | Ccrc - South Port Square, Llc |
| Ownership Type | For Profit - Individual |
| NPI Number | 1376957803 |
| Organization Name | CCRC - SOUTH PORT SQUARE, LLC |
| Doing Business As | HARBOUR HEALTH CENTER |
| Address | 23013 Westchester Blvd, Port Charlotte, FL 33980 |
| Phone Number | 941-625-1220 |
News Archive
2009 saw exciting research progress, unprecedented opportunities on the horizon, and more scientists than ever working on resolving important questions. Despite the year's economic and financial challenges, the National Multiple Sclerosis Society continues to propel research forward to end MS. In 2009 the Society provided over $33.5 million to support 345 new and ongoing projects in its research portfolio, plus $1.5 million for Fast Forward, the Society's drug development subsidiary which continues to attract new funding streams.
Researchers at Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago, and colleagues, discovered a promising direction toward understanding the development of necrotizing enterocolitis, a devastating intestinal disease commonly affecting premature infants, in order to treat it.
Researchers at the University of California, San Diego have discovered that a complex network of interactions between drugs and the proteins with which they bind can explain adverse drug effects. Their findings suggest that adverse drug effects might be minimized by using single or multiple drug therapies in order to fine-tune multiple off-target interactions.
In late-breaking clinical trial results presented in a Hot Line Session today at the European Society of Cardiology Congress 2019, investigators from Brigham and Women's Hospital and Greater Paris University Hospitals - AP-HP/Université de Paris presented the results from The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study, a clinical trial sponsored by AstraZeneca that evaluated whether adding ticagrelor to aspirin improves outcomes for patients with stable coronary artery disease and diabetes mellitus but without a history of heart attack or stroke.
ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to closing conditions, to acquire BeijingWits Medical Consulting Ltd., a leading CRO in China.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
2009 saw exciting research progress, unprecedented opportunities on the horizon, and more scientists than ever working on resolving important questions. Despite the year's economic and financial challenges, the National Multiple Sclerosis Society continues to propel research forward to end MS. In 2009 the Society provided over $33.5 million to support 345 new and ongoing projects in its research portfolio, plus $1.5 million for Fast Forward, the Society's drug development subsidiary which continues to attract new funding streams.
Researchers at Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago, and colleagues, discovered a promising direction toward understanding the development of necrotizing enterocolitis, a devastating intestinal disease commonly affecting premature infants, in order to treat it.
Researchers at the University of California, San Diego have discovered that a complex network of interactions between drugs and the proteins with which they bind can explain adverse drug effects. Their findings suggest that adverse drug effects might be minimized by using single or multiple drug therapies in order to fine-tune multiple off-target interactions.
In late-breaking clinical trial results presented in a Hot Line Session today at the European Society of Cardiology Congress 2019, investigators from Brigham and Women's Hospital and Greater Paris University Hospitals - AP-HP/Université de Paris presented the results from The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study, a clinical trial sponsored by AstraZeneca that evaluated whether adding ticagrelor to aspirin improves outcomes for patients with stable coronary artery disease and diabetes mellitus but without a history of heart attack or stroke.
ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to closing conditions, to acquire BeijingWits Medical Consulting Ltd., a leading CRO in China.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 23.26 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 7.89 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 87.8 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.77 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 7.07 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 2.87 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.23 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 6.25 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 99.22 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.91 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 28.67 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 16 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 11.4 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 92.94 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 69.26 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 83.44 | 82.93 |
News Archive
2009 saw exciting research progress, unprecedented opportunities on the horizon, and more scientists than ever working on resolving important questions. Despite the year's economic and financial challenges, the National Multiple Sclerosis Society continues to propel research forward to end MS. In 2009 the Society provided over $33.5 million to support 345 new and ongoing projects in its research portfolio, plus $1.5 million for Fast Forward, the Society's drug development subsidiary which continues to attract new funding streams.
Researchers at Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago, and colleagues, discovered a promising direction toward understanding the development of necrotizing enterocolitis, a devastating intestinal disease commonly affecting premature infants, in order to treat it.
Researchers at the University of California, San Diego have discovered that a complex network of interactions between drugs and the proteins with which they bind can explain adverse drug effects. Their findings suggest that adverse drug effects might be minimized by using single or multiple drug therapies in order to fine-tune multiple off-target interactions.
In late-breaking clinical trial results presented in a Hot Line Session today at the European Society of Cardiology Congress 2019, investigators from Brigham and Women's Hospital and Greater Paris University Hospitals - AP-HP/Université de Paris presented the results from The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study, a clinical trial sponsored by AstraZeneca that evaluated whether adding ticagrelor to aspirin improves outcomes for patients with stable coronary artery disease and diabetes mellitus but without a history of heart attack or stroke.
ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to closing conditions, to acquire BeijingWits Medical Consulting Ltd., a leading CRO in China.
› Verified 3 days ago
Signature Healthcare Of Port Charlotte Location: 4033 Beaver Lane, Port Charlotte, Florida 33952 Phone: (941) 625-3200 | |
Port Charlotte Rehabilitation Center Location: 25325 Rampart Blvd, Port Charlotte, Florida 33948 Phone: (941) 629-7466 | |
Harbour Health Center Location: 23013 Westchester Blvd, Port Charlotte, Florida 33980 Phone: (941) 625-1220 | |
Solaris Healthcare Charlotte Harbor Location: 4000 Kings Hwy, Port Charlotte, Florida 33980 Phone: (941) 255-5855 | |
Consulate Health Care Of Port Charlotte Location: 18480 Cochran Blvd, Port Charlotte, Florida 33948 Phone: (941) 743-4700 | |
Douglas Jacobson State Veterans Nursing Home Location: 21281 Grayton Terrace, Port Charlotte, Florida 33954 Phone: (941) 613-0919 |